 Cardiff Oncology Inc NASDAQ: CRDF has announced updated data from its Phase 2 trial evaluating the oral combination of onvansertib, Johnson Johnsons NYSE: JNJ Zytiga abiraterone, and prednisone for metastatic castrate-resistant prostate cancer mCRPC. Data were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium. 